Overview

Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Status:
Completed

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to understand if saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not controlled with diet and exercise

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Metformin
Saxagliptin